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Abstract
Although transformation of melanocytes to melanoma is rare, the rapid growth, systemic spread, as well as the
chemoresistance of melanoma present significant challenges for patient care. Here we review animal models of
melanoma, including murine, canine, equine, and zebrafish models, and detail the immense contribution these
models have made to our knowledge of human melanoma development, and to melanocyte biology. We also
highlight the opportunities for cross-species comparative genomic studies of melanoma to identify the key
molecular events that drive this complex disease.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Melanocytes produce melanin that protects skin from
the effects of ultraviolet light, and also reside as part
of mucosal tissues at sites such as the lower bowel,
anus, vulva, mouth, and upper aero-digestive tract.
Melanocytes are also found in the uvea/iris of the eye
and in the inner ear.
Genetic predisposition to melanoma in humans
Cutaneous melanoma is largely a malignancy of
fair-skinned people with familial and sporadic genetic
risk factors. Population-based genome-wide association
studies (GWAS) have been particularly informative
at defining the relevant melanoma risk regions in the
sporadic disease, and to date, around 20 genome-wide
significant loci have been identified [1,2]. These
include regions surrounding the melanocortin 1 recep-
tor (MC1R) and tyrosinase (TYR) genes. MC1R is a
G-protein coupled receptor located in the plasma mem-
brane that plays an important role in controlling the
microphthalmia-associated transcription factor (MITF)
gene (Figure 1). Disruptive mutations ofMC1R are asso-
ciated with red hair, freckling, and sun sensitivity due
to a failure in the processing of red/yellow pheomelanin
to brown/black eumelanin. Importantly, the function
of MC1R is highly conserved across species and
contributes to skin colouration in a range of higher ver-
tebrates and in fish [1,3]. Tyrosinase is the rate-limiting
enzyme in the production of melanin (variants of which
include eumelanin and pheomelanin, described above);
TYR is transcriptionally regulated by MITF binding
to its promoter. The oxidase activity of tyrosinase
converts dopa to dopaquinone, a precursor of melanin.
Mutations in tyrosinase result in a rare disorder called
oculocutaneous albinism [4,5], which is associated with
ultraviolet (UV) sensitivity, while common variants
associated with blue eyes have been linked to melanoma
predisposition by GWAS [2]. In addition to the MC1R
and TYR genes, a variant (E318K) in the aforementioned
MITF gene is associated with increased melanoma risk
in sporadic and familial cases, and is an intermediate
genetic risk factor [6]. Genes linked to naevus density
have also been implicated in disease development
(such as PLA2G6 and IRF4), with common variants
in or near these genes being revealed by GWAS [2,7].
Likewise, melanoma GWAS have identified variants
linked to the cyclin-dependent kinase inhibitor 2A
(CDKN2A) gene [1,2]. Importantly, loss-of-function
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Figure 1. Established melanoma pathways. The two major signalling pathways implicated in melanoma are the mitogen-activated protein
kinase and the phosphatidylinositol-4,5-bisphosphate 3-kinase pathways, which are in red and green, respectively. Key genes include c-KIT
(pink), CDK (blue), GNAQ/GNA11 (brown), MITF (orange), NRAS (yellow), and P53/BCL (purple). MC1R, which is involved in skin pigmentation,
and TERT and POT1, which are involved in telomere regulation, are also shown. This figure was modified from Vidwans et al [142] under
the Creative Commons Attribution License. The lines shown indicate known interactions between pathways or molecules.
mutations in CDKN2A, and its binding partner, the
product of the cyclin-dependent kinase 4 (CDK4)
gene, have been identified in highly melanoma-prone
families [8–10], firmly linking disruption of cell
cycle control and melanoma risk. In addition to the
abovementioned genes, recent work has implicated
components of the telomere regulation machinery as
playing important roles in melanomagenesis. First,
the telomerase reverse transcriptase gene (TERT) was
identified in GWAS studies, and by the analysis of a
familial melanoma pedigree, a−57 bp mutation creating
an ETS transcription factor binding site that activates
the TERT promoter was identified [11]. More recently,
melanoma family studies have identified the protection
of telomeres 1 gene (POT1), with mutations in the
DNA binding domain of POT1 dramatically increas-
ing telomere length and promoting telomere fragility
[12,13]. POT1 is a component of the shelterin complex,
which is a key regulator of telomere end-processing.
Other components of this complex have been shown
to be truncated in melanoma-prone families including
ACD and TERF2IP, but the exact consequences of
these mutations on telomere function are yet to be
defined [14].
While these genetic susceptibility studies have
defined the landscape of predisposition to cutaneous
melanoma, less is known about the germline genetic
contribution to other forms of melanoma. At present,
we know that rare loss-of-function variants in the BAP1
gene, encoding the BRCA1-associated protein-1 (ubiq-
uitin carboxy-terminal hydrolase), a deubiquitinating
enzyme, predispose to ocular melanoma, with some
patients also developing cutaneous melanomas and
tumours of other sites [15,16], yet these mutations
account for less than 10% of uveal melanoma families.
Little is known about the germline genetics of acral
and mucosal melanoma, due largely to the rarity of
these forms of the disease, and no association with pig-
mentation genes has been observed [17]. Some reports
have suggested that patients with Werner syndrome, a
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015
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DNA repair and ageing syndrome, have an increased
incidence of these cancers [17].
Genetic predisposition to melanoma in animals
With the exception of mutations in MC1R, few stud-
ies have addressed the genetics of predisposition to
melanoma development in animal models. The stud-
ies that have been performed have again revealing an
important role for genes that influence pigmentation in
the cutaneous disease. In horses, for example, a 4.6 kb
intronic mutation in the STX17 (syntaxin-17) gene was
found to be associated with a vitiligo-like depigmen-
tation phenotype and susceptibility to melanoma [18].
Cutaneous melanoma also occurs in dogs, with some
reports of differences in breed susceptibility suggest-
ing a genetic basis for melanoma risk [19]. Whether
melanoma susceptibility in dogs and horses, or indeed in
mice and fish, is mediated via the same genes and path-
ways as those in humans is not known. Thus, there is
a significant opportunity to use genetic studies in ani-
mal models to define new genes and loci that influence
melanoma risk, and to use these data to guide genetic
studies in humans.
Somatic mutations in human melanoma
Most of what has been learnt about the somatic genet-
ics of cutaneous melanoma in humans has been revealed
in the last 15 years. The family studies that identified
germline mutations in CDKN2A led to the identifica-
tion of somatic mutation in this gene, and also deletions
of the entire gene locus [9,20]. Likewise, studies that
identified the phosphatase and tensin homolog (PTEN)
gene as being mutated in glioma led to the identification
of mutations and deletions of this locus in melanoma
[21]. Studies in mouse melanoma models have con-
tributed significantly to our understanding of melanoma
and have established a key role for the mitogen-activated
protein kinase (MAPK) pathway in melanoma devel-
opment. In early studies, a HRASG12V transgene was
expressed in melanocytes, resulting in highly penetrant
melanoma formation [22]. Several years later, activating
mutations of the neuroblastoma RAS viral (v-ras) onco-
gene homolog (NRAS) gene were identified in human
melanomas at a frequency of 20% [23–25], and in
2002, amplicon sequencing studies of melanoma cell
lines resulted in the identification of activating BRAF
mutations, most converting a valine at position 600 to a
glutamic acid (BRAFV600E), generating a constitutively
active kinase in around 50% of cases [26]. The dis-
covery of this somatic mutation resulting in constitu-
tive activation of the MAPK pathway has revolutionized
the field of melanoma genetics and has recently facil-
itated a revolution in new therapeutics, with clinically
approved agents targeting mutant BRAF, and MEK and
ERK now in use [27]. More recently, next-generation
sequencing of melanomas and matched germline DNA
has identified as many as 20 genes as being statistically
significantly mutated in human melanoma [28–30].
Many of these genes are components of the MAPK
and phosphoinositide 3-kinase (PI3K) pathways, or cell
cycle regulatory genes such as the protein phosphatase
6, catalytic subunit (PPP6C), in addition to regula-
tors of the chromatin landscape (ARID2, ARID1A, and
ARID1B) [31–33]. While these studies have defined
the complexity of melanoma, they have also chal-
lenged the one-size-fits-all approach to disease man-
agement. Less is known about the genetics of the
non-cutaneous forms of melanoma but acral, uveal,
and mucosal melanomas tend to harbour mutations in
the guanine nucleotide-binding protein G(q) subunit
alpha (GNAQ), the guanine nucleotide binding pro-
tein (G protein), alpha 11 (Gq class) (GNA11), and
v-kit Hardy-Zuckerman 4 feline sarcoma viral onco-
gene homolog (c-KIT) genes [17]. Figure 1 provides an
overview of the established melanoma pathways.
Next-generation sequencing of human melanomas
brings ‘the end of the beginning’ for melanoma
gene discovery
To date, around 500 human melanoma germline/tumour
pairs have been sequenced, with these tumours being
largely of cutaneous origin and a limited number of acral
and mucosal origin [28–30,34,35]. Likewise, a limited
number of uveal melanomas have been sequenced
[28,30], although The Cancer Genome Atlas (TCGA)
is currently collecting tumours for sequencing and anal-
ysis. So what have these sequencing studies actually
taught us? First, the sequence has given us a clearer view
of the frequency of mutations in known driver genes.
Prior to these studies, we knew, for example, that BRAF
and NRAS mutations occurred but tumour sequencing
studies have helped us to resolve their absolute preva-
lence, particularly at positions outside of the canonical
BRAFV600 and NRASQ61 residues. Secondly, sequenc-
ing has identified new genes. For example, hotspot
mutations in PPP6C and RAC1 have been identified,
and represent potential sites for therapeutic targeting.
We knew previously that RAC GTPase activity could
contribute to melanoma development [36], but we had
no clear way of grappling with it mechanistically, or for
exploiting this knowledge in the clinic. The sequence of
human melanomas has also taught us something of the
constellations of mutations that occur within individual
tumours. We know now, for example, that the RAC1
P29S hotspot mutation is mutually exclusive frommuta-
tions in other components of the Rho family, a result that
would be predicted, but is clarifying nonetheless [30].
We have also learnt that there is a third subtype of cuta-
neous disease called NRAS/BRAF wild-type melanoma,
which is characterized by a high C>T mutation burden,
amplifications and mutation of c-KIT , and alterations
of NF1 [28,30]. More recently, a fourth subclass
called NRAS/BRAF/NF1 wild type has been proposed
[29]. While these studies have been broadly informa-
tive, melanomas rarely contain the same complement
of mutations, so how specific mutations co-operate
to promote tumour formation remains unanswered.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015
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Sequencing of human tumours has also informed us
that the major mutagen in cutaneous melanoma is UV
light which drives a C>T mutation pattern. It has also
revealed the potential role of other processes such as
oxidative stress [30]. Despite the apparent clarity that
sequencing has provided, there is still much to learn, and
integrating the sequence data with functional studies,
and studies in model systems will be key.
Using the mouse to model melanoma
There are multiple ways to model melanoma in
the mouse, to allow the identification of key onco-
genes/tumour suppressor genes involved in melanoma
initiation, progression, and metastasis, as well as for
the preclinical testing of therapeutics. Here we will out-
line the use of patient-derived xenografts, genetically
engineered mice, and melanoma cell lines.
Melanoma cell lines
Established human and mouse melanoma cell lines con-
tinue to be workhorses for mechanistic studies, as much
can be gained from their analysis. The B16 mouse
melanoma model was created in the 1970s from a
melanoma that developed spontaneously in a C57BL/6
mouse and was then passaged in vivo through ten rounds
of tail vein injection and collection of subsequent pul-
monary metastases to create the B16-F10 line [37]. This
cell line has been used in a plethora of tumour immunol-
ogy and metastasis studies [37,38].
In vitro work has its limitations (such as a lack
of extracellular matrix and 3D growth), and thus, the
use of human cell lines in vivo is frequently used
to model melanoma, usually by subcutaneous injec-
tion/engraftment into immunodeficient mice [typically
non-obese diabetic/severe combined immunodeficient
(NOD/SCID) mice] that do not produce lymphocytes
or NK cells. These cell line xenograft models allow
melanoma cells to directly establish interactions with
the stroma, the lymphatic system, and blood vessels.
Cell line xenografts have been widely used in determin-
ing drug responses [39]; however, cell lines are unde-
niably altered during adaptation to in vitro conditions
and long-term culture, limiting their usefulness in cer-
tain aspects of modelling human melanoma. In partic-
ular, their ability to predict clinical drug responses has
been widely questioned and critiqued [40].
Patient-derived xenograft (PDX) models
Patient-derived xenograft (PDX) or ‘tumourgraft’
samples are collected under ethical approval as fresh
biopsy tissue or fine needle aspirates and within
hours implanted subcutaneously into immunodeficient
mice [41]. A high degree of similarity, at the level
of expression and DNA sequence, has been demon-
strated between PDXs and donor tumours, with human
melanoma PDXs found to be predictive of metastasis
[42]. Excitingly, the utility of PDXs for informing
patient care was recently demonstrated, with PDXs
found to be predictive of patient drug response [43].
PDXmodels, however, do have several important lim-
itations – in particular, the absence of a fully functional
immune system – although it is possible to generate par-
tially ‘humanized mice’ using patient-derived CD34+
haematopoietic stem cells capturing some elements of
the human immune system [44].
Genetically engineered mice (GEM) models
Although mice rarely develop melanoma spontaneously,
they can do so when genetically engineered to carry
defined mutations that mimic the genetic lesions (or
their consequences) found in human melanomas. These
engineered mutations can result in activation of onco-
genes (such as mutant BrafV600E or NrasQ61R) and/or
inactivation of key tumour suppressor genes (such as
Cdkn2a or Pten). Examples of GEM models are listed
in Table 1 and shown in Figure 2. In mice, genetic
modification of the germline melanoma susceptibil-
ity gene Cdkn2a (p16Ink4a null mice) does not result
in melanoma, with these mice typically developing
soft-tissue sarcomas and lymphomas [45]. One way
around this is to use of compound GEM models. For
example, mice carrying melanocyte-specific (tyrosinase
promoter-controlled) expression of activated HRASG12V
on an Ink4a-deficient background develop spontaneous
cutaneous melanomas after a short latency and with a
high penetrance [22]. Interestingly, in addition to cuta-
neous melanomas, these mice also developed ocular
melanomas, as has been reported for mice carrying
melanocyte-specific expression of activated NRASQ61K
on an Ink4a-deficient background (Figure 2) [46]. Muta-
tional activation of BRAF in mice carrying condi-
tional melanocyte-specific expression of BrafV600E (or
the mouse equivalent, BrafV618E) has also been used to
model melanoma development, tumour progression, and
drug resistance [47–49].
Given the importance of UV light as a key mutagen in
the initiation of melanoma, GEMmodels of UV-induced
melanoma have been developed, such as HGF/SF mice,
which were used to show that a single dose of burning
UV radiation to neonates, but not adults, is necessary and
sufficient to induce melanomas with high penetrance,
thus providing experimental support for epidemiologi-
cal evidence that suggests that childhood sunburn poses
a significant risk for developing melanoma [50]. More
recently, neonatal UVB exposure was shown to accel-
erate melanoma growth and enhance distant metastases
in Hgf-Cdk4R24C mice [51], and pulmonary metastasis
of melanomas in adult Hgf-Cdk4R24C mice was found
to occur after treatment with the mutagen DMBA and
repeated UVB exposure [52]. The Hgf-Cdk4R24C model
has also been used to generate metastatic melanoma by
introducing p16-null and Nme23-null alleles [53,54].
GEM models have the advantage over other sys-
tems of autochthonous tumour development in an envi-
ronment where the tumour cells interact reciprocally
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015
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Table 1. Examples of genetically engineered mouse (GEM) models of melanoma
GEM name Genes involved Phenotype Reference
MT/ret Transgenic mice with the RET
proto-oncogene fused to the
mouse metallothionein
promoter-enhancer
• Mice develop hyperpigmented skin due to aberrant melanogen-
esis and melanocytic tumours develop but do not metastasize
• The transgenic line ‘304/B6’ (which has been back-crossed to
C57BL/6 for ten generations) spontaneously develops systemic
skin melanosis, benign melanocytic tumours, and melanoma
that undergoes metastasis to distant organs
• On a background of Ednrb heterozygosity, these mice show
late-onset melanoma development with a high percentage of
metastasis, and poor prognosis after tumour development
Iwamoto et al
[136]
Kato et al [137]
Kumasaka et al
[138]
HGF/SF Transgenic mice with the
metallothionein promoter
driving overexpression of
hepatocyte growth
factor/scatter factor (HGF/SF)
• The skin of these mice has melanocytes in the dermis, epider-
mis, and dermal–epidermal junction, and thus this model is
more akin to human skin
• Aged HGF/SF -transgenic mice develop sporadic melanoma
with metastasis
• Cutaneous melanomas arise in UV-irradiated
HGF/SF -transgenic mice in distinct stages that resemble
human disease, including grossly identifiable premalignant
lesions, intermediate radial and vertical growth stages of
heterogeneous histopathologies, and late metastatic spread to
a variety of distant organs
Takayama et al
[139] Noonan
et al [50,140]
p16Ink4a−/− A p16Ink4a-specific knockout
mouse that retains normal
p19Arf function
• Although these mice develop melanomas, they more preferen-
tially develop soft-tissue sarcoma and/or splenic lymphoma
Sharpless et al [45]
Tyr-HRAS Transgenic mice with mouse
tyrosinase gene promoter
driving overexpression of an
oncogenic form of HRAS
(HRASG12V)
• These mice spontaneously developed cutaneous and ocu-
lar tumours that are locally invasive and do not undergo
metastasis
• The incidence and latency of melanoma development are accel-
erated on an Ink4a-deficient background
Chin et al [22]
Tyr::NRASQ61K Transgenic mice with mouse
tyrosinase gene promoter
driving overexpression of a
dominant-active human NRAS
(NRASQ61K)
• Mice showed hyperpigmented skin and develop cutaneous
metastasizing melanoma
• On an Ink4a-deficient background, > 90% of the mice devel-
oped melanomas that at 6 months micro-invade the epidermis
and disseminate to lymph nodes, lung, and liver
Ackermann et al
[135]
Hgf-Cdk4R24C Overexpression of the hepatocyte
growth factor (HGF) and an
oncogenic mutation in
cyclin-dependent kinase 4
(CDK4)R24C
• These mice rapidly develop multiple invasive melanomas in
the skin following neonatal or adult carcinogen treatment
(UV and/or DMBA), which spontaneously metastasize to lymph
nodes and lungs
• Primary DMBA-induced melanomas have been used to derive
cell lines that when subcutaneously administered to C57BL/6
immunocompetent mice, spontaneously develop lung metas-
tases
Tormo et al [141]
Gaffal et al [51]
Bald et al [52]
LSL-BrafV600E Conditional expression of
BrafV600E from the endogenous
Braf locus
• When crossed with Tyr::CreER mice and tamoxifen was rubbed
on their skin, these mice showed skin hyperpigmentation and
the appearance of naevi harbouring senescent melanocytes,
with ∼70% developing melanomas
• On a p16INK4a null background, these mice developed
melanoma with increased penetrance and decreased latency
Dhomen et al [47]
Braf CA Conditional expression of
BrafV600E from the endogenous
Braf gene
• When crossed with Tyr::CreER mice and tamoxifen is rubbed on
their skin, these mice develop benign melanocytic hyperplasias
that fail to progress to melanoma over 15–20 months
• On a Pten null background, these mice developed melanoma
with 100% penetrance, short latency, and metastases (lymph
nodes and lungs)
• Melanoma development was prevented by inhibitors of mTorc1
(rapamycin) or MEK1/2 (PD325901) but only whilst the drug
was being administered (cessation of administration led to
melanoma development). Combined rapamycin and PD325901
treatment led to shrinkage of established melanomas
Dankort et al [49]
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015
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Table 1. Continued
GEM name Genes involved Phenotype Reference
LSL-BrafV618E Conditional expression of BrafV618E from
the endogenous murine Braf gene
(BrafV618E is analogous to BRAFV600E in
humans).
• When crossed with Tyr::CreER mice and tamoxifen was
rubbed on their skin, these mice showed skin hyperpigmen-
tation and naevi with ∼80% developing melanoma
• Sleeping Beauty insertional mutagenesis in this model
accelerated melanoma latency and penetrance. Treatment
with the BRAF inhibitor PLX4720 resulted in tumour
regression followed by relapse, and analysis of transpo-
son insertion sites in these melanomas identified putative
mediators of resistance
Perna et al [48]
LSL= lox-STOP-lox .
Figure 2. Naevi and melanomas driven by oncogenic forms of Braf and NRAS. (A, B) Naevi developing in adult BrafV618E mice [48]. Naevi
generally became visible 6–8 weeks after the induction of BrafV618E expression. (C, D) Melanoma from the same BrafV618E model. D shows
an invasive malignant melanoma with evidence of infiltration and destruction of the overlying surface epithelium and invasion into the
subcutaneous adipose tissue. The average latency to melanoma formation was 426 days in this model. (E) H&E-stained section of an ocular
melanoma, with melanoma cell infiltration of the lens and the subretinal tissues, that developed in a 13-week-old Tyr::NRASQ61K mouse
[135]. Original magnification× 50.
with the immune system and other components of
the microenvironment. Disadvantages of GEM models
include their expense and the fact that tumours often
arise after a long latency (9–12 months) and gener-
ally do not carry the mutagenic load found in human
tumours. Regardless of these factors, these models have
made a fundamental contribution to our understanding
of melanoma development.
Using the dog to model melanoma
Dogs as spontaneous models of melanoma
Malignant melanoma is a relatively common cancer in
domestic dogs and represents a unique model of human
melanoma that is highly heterogeneous and arises
and metastasizes spontaneously in an immunocompe-
tent animal. There is potential to relate the molecular
character of individual tumours to clinical outcome, as
pet dogs receive therapy ranging from surgery, radiation,
and cytotoxic chemotherapy through to molecularly tar-
geted therapy and immunotherapy. Here we will review
the utility of canine melanoma as a comparative model
and as a preclinical model of human melanoma.
Incidence, anatomic location, and clinical
progression of melanoma in dogs
Many domestic animals develop spontaneous
melanocytic neoplasms, including dogs, cats, horses,
and pigs. Malignant melanoma is more common in the
dog compared with other species and the majority of
cases arise in the oral cavity (mucosal), with haired
skin (cutaneous), nailbed epithelium and footpad (sub-
ungual and acral), and ocular (uveal) locations being
less common [55] (Figure 3). Canine oral melanoma is
highly aggressive with frequent metastases, especially to
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015
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Figure 3. Canine, equine, and zebrafish melanoma. (A) A canine melanoma developing in the nasal cavity and (B) spreading to the viscera,
particularly the liver. (C) An equine melanoma showing multinodular dermal lesions around the tail base and masses expanding into the
pelvic canal and regional nodes. (D) An equine spleen with multiple malignant melanomas, and liver and lymph node from the same case.
(E) Melanomas arising in a BRAFV600E; mitf zebrafish and (F) in a BRAFV600E; p53 zebrafish. The photographs in A and B were kindly provided
by Jeff Caswell, Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada N1G2W1.
local lymph nodes and lungs. In contrast to human cuta-
neous melanomas, dog cutaneous melanomas are most
often benign [55]. Some dog breeds are over-represented
in oral melanoma studies and may be predisposed to
developing the disease. In a study of 2350 dogs with
melanocytic tumours, poodles, Beauce shepherds, rot-
tweilers, schnauzers, Scottish terriers, and Labrador
retrievers had a higher percentage of these tumours
than other breeds [56]. In general, this study also found
that black-coated breeds were over-represented and that
pale or white-coated breeds were under-represented in
terms of developing melanocytic tumours. Conventional
treatment for oral melanoma in dogs involves surgical
resection and/or radiation of the primary tumour to
control local disease [57], while treatment of metastatic
disease is much less successful. Most metastases are
resistant to chemotherapy and a variety of immunother-
apeutic approaches have been attempted [58]. A
commercially produced melanoma vaccine (ONCEPT,
Sanofi) is available and has shown efficacy in canine
melanoma compared with historical controls [59], but
there is controversy as to the level of effect when there
has not been a randomized trial [60], and some stud-
ies have failed to show an effect on clinical outcome
[61]. Other immunomodulatory approaches have been
applied experimentally in small groups of dogs and
show some potential [62,63]. As described in more
detail below, there are a number of receptor tyrosine
kinase genes that are mutated in canine melanomas and
tyrosine kinase inhibitor drugs are already commercially
available and used clinically in canine cancer patients
[64], but to date no trials have been published using
these compounds in canine melanoma.
Genetics of canine melanoma
The complete canine genome sequence was first
released in 2005 [65], revealing a significant shared
ancestral sequence in common with humans. Indeed,
canine DNA and protein sequences are more similar to
humans than are those of mice [65]. Due to this simi-
larity, molecular tools for studying canine diseases are
quite advanced, especially since a large proportion of
antibodies raised against human antigens work equally
well against canine proteins. Canine oral melanoma
does not have UV radiation as a risk factor, so it is not
surprising that the spectrum of mutations differs from
human cutaneous melanoma. The BRAFV600E mutation
is found in about 6% of canine oral melanomas [66],
as are non-canonical BRAF mutations. NRAS mutations
have also been found at the same location as those in
human melanoma (the residue corresponding to Q61),
and loss-of-function mutations in PTEN have been
reported [56]. Also similar to humans, loss of PTEN
expression, and c-KIT mutation, and/or overexpression
of c-KIT are common in the canine disease. Importantly,
comparative copy number studies have been performed
between dog and human melanomas of mucosal and
acral origin, suggesting that in concordance with what
is known for human melanomas, canine melanomas of
the oral mucosa and cutaneous epithelium are discrete
and initiated by different molecular pathways [67].
Canine melanoma as a preclinical model
The overall success rate of translating cancer therapies
from murine preclinical models to treatments with clin-
ical utility in humans is estimated to be around 5%
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[68]. Although the increasingly sophisticated mouse in
vivomodelling systems described above are more likely
to capture the complexity of human cancer than the
less refined systems used in the past, a complemen-
tary approach is to include dogs with spontaneous can-
cers [69]. Until recently, humans could be considered a
preclinical model for dogs; the majority of drugs used
in veterinary medicine are derived from drugs initially
designed and tested for efficacy in humans. There is an
organized network for conducting clinical trials in dogs
with cancer across the United States and Canada orga-
nized through the National Cancer Institute, called the
Comparative Oncology Trials Consortium [70,71]. This
allows for multi-centre clinical trials with defined inclu-
sion and exclusion criteria, much like human clinical tri-
als [71]. From the perspective of the veterinary patients
and their owners, the access to investigational therapies
is a clinical trial; from the perspective of human patients,
these can be thought of as preclinical trials. This has led
to the concept of co-clinical trials, where both human
and canine patients with the same tumour type, or muta-
tion spectrum, receive the same drugs [72]. In addition
to mirroring the heterogeneity and complexity of spon-
taneously arising cancer, dog trials have other practical
advantages; the contracted disease timeline allows ear-
lier assessment of effects on disease progression and
overall survival, since the lifespan of dogs is far shorter
than that of humans and canine cancers progress more
quickly in general. Furthermore, new drugs are com-
monly tested for toxicity in laboratory beagles, so the
initial safety and sometimes the pharmacodynamics and
pharmacokinetics are already known for dogs.
A recent, excellent study by Simpson et al [73]
explored the utility of canine melanoma as a model of
the human disease, and readers are referred there for
a more in-depth review. The consensus of that group
was that there are substantial clinical and histopatho-
logical similarities between mucosal melanomas in
the two species. The Simpson study leveraged the
Canine Comparative Oncology and Genomics Con-
sortium (http://www.CCOGC.net), which contains a
large collection of canine tumours including matched
dog melanoma/normal pairs. To date, there have been
relatively few large clinical trials in canine melanoma.
The development of the canine melanoma vaccine
introduced above involved only 58 patients [59]. As in
humans, the majority of melanoma therapies tried in
dogs have failed, which although discouraging, might be
considered evidence for the utility of canine melanoma
as a model. As canine melanoma is a heterogeneous
cancer, has developed in the context of an intact immune
system, and occurs in a genetically heterogeneous pop-
ulation of animals, only the most robust investigational
drugs will be able to show efficacy in a clinical trial.
Thus, although the majority of melanomas forming in
dogs are of mucosal origin, and thus rarer in frequency
than common melanomas in humans which are cuta-
neous, there are significant opportunities in studying
dog melanomas alongside those of human and other
species.
Using the horse to model melanoma
Incidence, anatomic location, and clinical
progression of melanocytic tumours in horses
Melanocytic tumours are common tumours of horses,
representing approximately 4–8% of all tumours [74]
and up to 19% of cutaneous tumours [75,76].
As in other species, the terminology and classification
of melanocytic tumours in horses has been inconsistent
over time and has led to confusion between clinicians
and pathologists [77]. Four clinical syndromes are
currently recognized in horses: melanocytic naevi
(sometimes referred to as melanocytoma); dermal
melanomas; dermal melanomatosis; and anaplastic
malignant melanoma [78]. Some of the melanocytic
naevi resemble human naevi [79], and these occur in
both grey and non-grey horses, usually on the legs,
body or neck rather than the perineal region. Equine
dermal melanomas and dermal melanomatosis are
histopathologically similar, distinguished by their clin-
ical presentation; the former tend to be solitary discrete
tumours, whereas dermal melanomatosis presents as
multifocal dermal lesions, often coalescing and usually
occurring in typical locations (most commonly the
genital or tail base/perineal region, and less commonly
periocular and perioral). Dermal melanomatosis is
a disease of grey and white horses, and beyond the
age of 15 years, at least 80% of grey horses will have
melanomas at some location [78,80]. While they usually
have a benign initial presentation, they often develop
multi-centrically and are often associated with blood
vessels [for example, in the wall of the guttural pouches
(paired air-filled chambers formed from outpouching
of the Eustacian tube), around the parotid salivary
glands and lymph nodes, paralumbar, peri-aortic and
neck/carotid region]. In addition, many will progress
to true malignant forms with lymphatic and visceral
metastases [81]. Malignant forms occur in both grey and
non-grey horses, although the risk of malignant transfor-
mation may be greater in non-grey horses [75]. At least
in grey horses, histopathological features do not reliably
predict malignant behaviour [82], although application
of new biomarkers, such as RACK1, may show promise
[83]. Ocular [84] andmucosalmelanomas [85,86] are far
less common in horses than in other domestic species.
Equine melanoma as a comparative model
As in canine melanomas, equine melanomas are not
thought to be associated with exposure to UV light.
Development of the grey hair coat colour in horses with
age is an autosomal dominant trait associated with a high
incidence of melanoma, and also vitiligo-like depigmen-
tation [18]. The causative mutation for this phenotype
is a 4.6-kb intronic duplication in the STX17 (syntaxin
17) gene, which constitutes a cis-acting regulatory
mutation. Both STX17 and the neighbouring NR4A3
gene are overexpressed in melanomas from grey horses.
It is known that the duplication in STX17 is strongly
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associated with constitutive activation of the ERK
pathway in melanocytic cells from grey horses, high-
lighting the universal importance of the MAPK/ERK
pathway in melanomagenesis [87]. Further, experi-
mental models using reporter constructs in transgenic
zebrafish have demonstrated that the duplicated STX17
sequence acts as a strong enhancer in neural crest
cells and has subsequent melanophore-specific activity
during embryonic development, consistent with the
phenotypic manifestation of the mutation in horses [88].
This study went on to demonstrate that one region of
the construct up-regulated the reporter gene expression
in a melanocyte-specific manner and contained two
microphthalmia-associated transcription factor (MITF)
binding sites, which are good candidates for mediating
the melanocyte-specific activity of the duplication.
As in other species, tumour subtype and breed/
individual variation (germline genetics) are likely to
influence the phenotype of the melanomas formed [89].
Indeed, grey horses that possess a loss-of-function
mutation in the ASIP (agouti signalling protein)
gene have a higher incidence of melanoma, impli-
cating melanocortin-1 receptor signalling in melanoma
development in these animals [18].
In terms of biological behaviour, grey horse
melanomas usually have an extended period of benign
growth, prior to malignant transformation and metasta-
sis, in contrast to most human melanomas, which metas-
tasize early. In vitro cell lines of primary and metastatic
horse melanomas revealed expression of p53, while
expression of the tumour suppressors p16 and PTEN
was absent from the metastatic line [90], potentially
implicating the latter pathways in disease progression.
In terms of histopathology, animal-type melanoma
in humans represents a rare distinct melanoma subtype,
characterized by proliferation of heavily pigmented
epithelioid and spindled melanocytes, that resembles
the heavily pigmented melanomas seen in grey horses
[91,92]. In humans, the disease has a young age of
onset (median 35 years old) and is considered to be
more indolent than conventional melanoma; it has a
tendency for regional lymphatic metastasis but infre-
quently progresses to disseminated metastatic disease
and death. Direct comparison of the genetic and molec-
ular alterations in human and equine melanomas will
provide fascinating insights into the mechanisms of
melanomagenesis [93].
Using zebrafish to model melanoma
The translational impact of zebrafish models
of melanoma
Modelling melanoma in zebrafish provides important
opportunities for in vivo imaging, chemical screens, and
genetics. Zebrafish cancers, including melanoma, share
many histopathological features with human cancers,
and molecular signatures closely align with those of
human cancer. Here we outline the use of genetically
engineered zebrafish and xenograft models, and discuss
how zebrafish have become instrumental for chemical
screens for drug leads and repurposing for melanoma.
Genetically engineered zebrafish (GEZ) models
The zebrafish genome shares over 70% similarity
with the human genome, and over 80% of human
disease genes – including oncogenes and tumour sup-
pressors – have orthologs in zebrafish [94]. Zebrafish
cancer models have primarily depended on transgenic
expression of oncogenes and N-ethyl-N-nitrosourea
(ENU)-induced genetic mutations in tumour suppres-
sor genes. However, the advent of genome editing
with the clustered regularly interspaced short palin-
dromic repeats (CRISPR) system now enables precise
and tissue-specific genetic editing that will enable more
refined genetic modelling of human melanoma [95–99].
In the first zebrafish melanoma model, human
BRAFV600E protein expressed from the melanocyte
mitfa promoter led to the generation of naevi, and a
mutation in p53 (p53−/−) was required for progression
to melanoma [100]. This was the first animal model
of the BRAFV600E mutation and was consistent with
genetics in human patients whereby expression of
BRAFV600E is sufficient to drive naevi, but requires
additional mutations for progression of melanoma from
naevi [26]. Building on the BRAFV600E;p53−/− model,
Zon and colleagues generated a modified zebrafish
whereby the BRAFV600E transgene was co-expressed
with one of 17 candidate genes from a recurrently
amplified region in human melanoma on chromosome
1q21 [101]. Screening for genes that promoted the rapid
onset of melanoma, they discovered that overexpression
of the histone methyltransferase SETDB1 can accelerate
the onset and invasion of melanoma. High expression
levels of SETDB1 are common in human melanoma
and indicate that changes in chromatin factors may be
critical in melanoma progression through changes in
gene regulation, such as the hox genes [101].
An important feature of zebrafish melanoma is
the ability to study melanocyte development genes
and how the lineage can become misregulated in
melanoma [102]. The master melanocyte transcription
factor MITF is a melanoma oncogene and has been
implicated in melanoma drug resistance, but until
recently it had not been modelled in an animal. A
unique temperature-sensitive mitf mutation in zebrafish
(mitfavc7) has recently been used to study MITF activity
in the control of melanocyte proliferation and differen-
tiation in embryogenesis, and as a cancer gene in the
development and survival of melanoma [103–105].
RAS mutations have also been modelled in zebrafish.
Expression of HRASG12V (HRAS12V) protein in
kit-expressing melanocyte progenitors is sufficient
to drive rapid expansion of melanocyte numbers in the
larval form andmelanoma in the adult, and this is depen-
dent on PI3K signalling [106]. Co-operation studies
have also demonstrated that elevated RAC activity, often
associated with melanoma in humans, can accelerate the
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progression of HRASV12-driven malignant melanoma
[107]. While HRASV12 melanoma studies have helped
to establish melanoma models important for drug
screens and cell biology studies [108], NRAS mutations
are the common RAS family melanoma mutation, and
genetic models in zebrafish indicate that NRASQ61K
mutations in melanocytes require co-operation with loss
of p53 to promote melanoma [109].
As with mice, limitations of the zebrafish BRAFV600E
models include the lengthy time for spontaneous tumour
formation and that genetically engineered animals do
not seem to have the diversity and number of muta-
tions found in human melanomas [110]. Accelerating
tumour formation with HRASV12 mutations enables
melanoma to be visualized at the earliest stages in the
zebrafish [106,108]. Zebrafish embryos and larvae are
transparent, enabling details of cell biology and the lin-
eage to be visualized in living animals. An important
example of this is the interactions of the immune sys-
tem with HRASV12 oncogene-expressing melanocytes at
the very earliest stages of neoplasia. Immune cells pro-
vide trophic support to HRASV12 oncogene-expressing
melanocytes [111,112].
Transplantation models of melanoma in zebrafish
Transplantation assays are fundamental to under-
standing cancer cell malignancy, migration, and
cancer-initiating cells. Zebrafish provide transplantation
studies at three stages: the early embryo, the larvae, and
the adult animal [113]. Transplantation into the early
embryo (prior to gastrulation) has been used to identify
important melanoma pathways, such as nodal via the
generation of an ectopic developmental axis [114–117].
Transplantation of human cancer cells into the larval
stage can lead to melanoma masses within a few days,
and enables the study of tumour-induced vasculariza-
tion and cancer cell metastatic spread. The availability
of lines with fluorescently labelled vasculature, such as
fli-GFP, allows for angiogenesis or lymphoangiogenesis
to be visualized in living animals [118,119]. Fluores-
cently labelled melanoma cells can also be visualized in
the process of co-operative behaviours during invasion
in zebrafish embryos [120]. An advantage to these
early-stage transplantation studies is the large number
of zebrafish that can easily be injected and that can be
coupled to live confocal imaging [121]. The zebrafish
immune system in these early stages primarily consists
of innate immune cells, and the adult immune system
is not fully functional until 28 days of development
[113]. In some cases, transplanted melanoma cells
have capitalized on neutrophil migration routes to new
metastatic niches [122].
Adult transplantation studies in zebrafish have been
important for assessing tumour potential, visualizing
cancer homing andmetastasis, and in competitive assays
for tumourigenicity. Important considerations in adult
transplantation studies include the need to suppress the
immune system. To get around these issues, immuno-
suppression can be induced by gamma irradiation
prior to transplantation (eg 20–25Gy), or dexametha-
sone in larval/juvenile fish, and isogenic strains have
recently become available [113]. Adult zebrafish are
no longer transparent, preventing detailed visualization
of engrafted tumours in living animals. Recently, a
transparent adult fish, called casper, has been generated
that enables visualization of transplanted melanoma
cells – either by their endogenous black pigmentation
or via a fluorescent transgene – at the single cell level
[102,123,124]. Limitations of the adult transplantation
studies are that human cancer cells do not engraft due
to immunogenicity and that most cells are injected
via intraperitoneal injection rather than orthotopically
[113].
Small molecule and drug screening in zebrafish
A unique feature of the zebrafish system is the ability
to treat the whole organism with drug treatments by
administering chemical compounds to the water [125].
This approach can be used to directly test the function of
a targetable pathway in transplantation studies, to screen
for new drug leads during early embryogenesis, and
for testing compounds in adult zebrafish cancer models
[126]. Examples include small molecule screens on the
melanocyte lineage that identified 5-nitrofuran com-
pounds, which are also effective in human melanoma
[127], and the changes caused by BRAFV600E;p53
at the embryonic level that identified leflunomide,
which is currently in clinical trials for melanoma [126]
(Clinical trials.gov identifier NCT01611675). Over-
all, phenotypic small molecule screening in zebrafish
is proving effective at multiple stages of the drug
discovery pipeline including hit identification, target
identification, lead optimization, and preclinical animal
modelling [128,129].
Other models of melanoma not discussed here include
the Sinclair swine model [130], which shows sponta-
neous regression; the Libechov minipig model [131];
and 3D human to mouse transplant models [132]. There
are also Xiphophorus models [133] and an opossum
melanoma model [134].
Conclusion
Perspectives and relevance of animal models
to melanoma in humans
Animal model studies in a range of species confirm the
‘naevus–melanoma’ pathway as the major sequence
of pathological progression to melanocytic malig-
nancy. They also establish naevi as neoplasms that
have mutations in oncogenes and tumour suppressor
genes, as opposed to the previously held pathologi-
cal view of naevi as non-neoplastic hamartomas. The
experimental animal model studies demonstrate that
some cancer genes (such as BRAF, NRAS,MITF, TP53,
P16/CDKN2A, BAP1, PTEN, C-KIT , etc) can drive
naevus formation and/or progression to melanoma in
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various combinations, while sequencing studies of
human melanomas emphasize the genetic heterogeneity
of the disease with potential for reclassification based
on the genetic phenotype in the future. Multi-species
comparative pathology and genomics (human, mouse,
zebrafish, dog, horse, other) help to identify new
melanoma genes for cutaneous melanoma, mucosal
melanoma, and less common melanomas at other sites,
including the study of rare subtypes of melanoma.
These molecular studies also shed light on melanoma
progression genes that influence the stage or aggressive
behaviour of the melanoma, potentially contributing
to an improved molecular and mechanistic under-
standing of melanoma progression to metastasis in
patients and serving as predictors of outcome or poten-
tial therapeutic targets. Small animal models (such
as mouse or zebrafish) are informative for preclinical
drug testing and investigation of mechanisms of drug
resistance, as well as providing new insights into the
melanoma–immune system interactions, which are of
increasing relevance to patient therapy.
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